# STOCKHOLM 1.0
#=GF ID   GSK-3_bind
#=GF AC   PF05350.16
#=GF DE   Glycogen synthase kinase-3 binding
#=GF AU   Finn RD;0000-0001-8626-2148
#=GF SE   Pfam-B_18811 (release 7.8)
#=GF GA   25.00 25.00;
#=GF TC   25.10 25.10;
#=GF NC   24.20 24.90;
#=GF BM   hmmbuild HMM.ann SEED.ann
#=GF SM   hmmsearch -Z 75585367 --cpu 4 -E 1000 HMM pfamseq
#=GF TP   Family
#=GF RN   [1]
#=GF RM   11738041
#=GF RT   The structure of phosphorylated GSK-3beta complexed with a
#=GF RT   peptide, FRATtide, that inhibits beta-catenin phosphorylation. 
#=GF RA   Bax B, Carter PS, Lewis C, Guy AR, Bridges A, Tanner R, Pettman
#=GF RA   G, Mannix C, Culbert AA, Brown MJ, Smith DG, Reith AD; 
#=GF RL   Structure (Camb) 2001;9:1143-1152.
#=GF DR   INTERPRO; IPR008014;
#=GF DR   SCOP; 1gng; fa;
#=GF DR   SO; 0100021; polypeptide_conserved_region;
#=GF CC   Glycogen synthase kinase-3 (GSK-3) sequentially phosphorylates
#=GF CC   four  serine residues on glycogen synthase (GS), in the sequence
#=GF CC    SxxxSxxxSxxx-SxxxS(p), by recognising and phosphorylating the
#=GF CC   first  serine in the sequence motif SxxxS(P) (where S(p)
#=GF CC   represents a  phosphoserine). Interaction of GSK-3 with a
#=GF CC   peptide derived from GSK-3 binding protein (this family)
#=GF CC   prevents GSK-3 interaction with Axin. This interaction thereby
#=GF CC   inhibits the Axin-dependent phosphorylation of  beta-catenin by
#=GF CC   GSK-3 [1]. 
#=GF SQ   7
#=GS I3MDQ9_ICTTR/1-236  AC I3MDQ9.1
#=GS FRAT1_MOUSE/1-233   AC P70339.2
#=GS G3INT8_CRIGR/1-235  AC G3INT8.1
#=GS FRAT2_HUMAN/1-214   AC O75474.3
#=GS H0Y0G4_OTOGA/1-237  AC H0Y0G4.1
#=GS G1SPD8_RABIT/8-221  AC G1SPD8.2
#=GS E1BNA0_BOVIN/1-234  AC E1BNA0.2
I3MDQ9_ICTTR/1-236             MPCRREEEEEAGEEAEGEEEDDDDSFLLLKQSVTLEGSGEVDRLVAQIGQTLQLDAAHDSPASRCVPPGPPLQPP...VA.LPADKARSPAVPLLLRPVSAEAGGLAPPGALRCALGDRGRVRGRAAPYCVAELSSGPSALSPLSSQPGLDGPPGAGKQGIPQPLTGPCRRGWLRSAAASRRLQQRRGSQPDTCTG.DDDPHRLLQQLVLSGNLIKEAVRRLHSRRLQLHAKLPQHRLLGP
FRAT1_MOUSE/1-233              MPCRREEEEEAGDEAEGEED..DDSFLLLQQSVTLGGSTDVDQLIVQIGETLQLDAAHDRPASPCAAPGPP..PPQVLAA.LPADKTGTPARRLLRPTGSAETGNPAPPGAVRCVLGERGRVRGRSAPYCVAEISPGASAL...PQQPGLDGPPGTGKLSTPQPLSGPCRRGWLRNAAASRRLQQRRGSQPETRTGDDDDPHRLLQQLVLSGNLIKEAVRRLHSRQLQLHAKLPAHPFLGP
G3INT8_CRIGR/1-235             MQCQRAEKEEGGFEAEGEDK..DDSFLLLQQSVTLGSLTDVDQLIALIGETLKLDTAHDGPASPSAAPGPP..PLRVLAA.ISVEQNRSPSRQMLRSSVPAETGAPAHPRAISCMLWERWRLRSQAAPYCVAELTAVTSALCPVSRQPGLEGPPVTGKPSTPQPLSGPCRRGWPQSTAMSLPLQQRPGSQPETHTS.DDDPHQLPQQLLLSGNLIKEAVQRLHSLQLQLQANLYSHRFLKR
FRAT2_HUMAN/1-214              MPCRREEEEEAGEEAEGEEE.EDDSFLLLQQSVTLGSSGEVDRLVAQIGETLQLDAAQDSPASPCAPPGVPLRAPGPLAAAVPADKARPPAVPLLLPPASAETVGPAPSGALRCALGDRGRVRGRAAPYCVAEVAAGPSALP........................GPCRRGWLRDAVTSRRLQQRRWTQAGARAG.DDDPHRLLQQLVLSGNLIKEAVRRLQRAVAAVAATGPASA.PGP
H0Y0G4_OTOGA/1-237             MPCRREEEEEAGEEAEGEEE..KDSFLLLEQSVTLGSSGEVDKLVAQIGETLQLDAAQDSPASPCASLGAPLRAPRPQAA.VRADEGPAAAVQLLLPPSSSEGVGPAPPGALRCALGDRGRVRGRAAPYCVAELVAGPSALPTLPLQPGQDGPLGAGKRGVSQQLSGPCRRGWLRGAAASRRLQQRRGSQPETRTN.DDDPHRLLQQLVLSGNLIKEAVRRLHSRRLQLHTKLPQRPLLGP
G1SPD8_RABIT/8-221             EEEAGEEAEGEEEEEEEEEE.EEGSFLLLEQSVTLGGSGEVDRLVAQIGETLQLDAAQDSPASPCAPPGRHSSSPRGLRR.GEGGQGLVPRRAAAAPPIVGRGGVTAPPVLFAAPSGTVPPCLGGLPPIVWSEL........................QGIPQPLSGPCRRGWLRGAASSRRLQQRRGSQPETRTS.DDDPHRLLQQLVLSGNLIKEAVRRLHSRRLQLRPKLPPCQLPGP
E1BNA0_BOVIN/1-234             MPCRREEEEEAGEEEE.....EEDSFLLLEQSVTVGGSVEVDRLVAQIGETLQLDAAQDRPASACAPPGPPLQPPRSPAA.VRADKARAPAQPLLLPAASIEAGGPAPLGALRCALGDRGRVRGRAAPYFVAELAAGPTALSPLPPQPSLDGPLGADKRGSPQPLSGPCRRGWLRDAAASRRLQHRRGLQPPARNG.DDDPHRLLQQLVLSGNLIKEAVRRLHSRRLQLHAKLPQRQLLGP
#=GC seq_cons                  MPCRREEEEEAGEEAEGEE-..-DSFLLLpQSVTLGuSsEVD+LVAQIGETLQLDAApDuPASPCAsPGsP.psPps.AA.l.ADcutsPAh.LLhPssSuEsGuPAPPGAlRCsLG-RGRVRGRAAPYCVAELsuGsSALs..s.QPu.-GP.sssK.uhPQPLSGPCRRGWLRsAAuSRRLQQRRGSQP-TRTu.DDDPHRLLQQLVLSGNLIKEAVRRLHSRpLQL+AKLPt+thLGP
